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Abstract
Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third most lethal
cancer worldwide. The epithelial to mesenchymal transition (EMT) describes the transformation of well-differentiated
epithelial cells to a de-differentiated phenotype and plays a central role in the invasion and intrahepatic metastasis of HCC
cells. Modulation of the transforming growth factor-β (TGF-β) signaling is known to induce various tumor-promoting and
EMT-inducing pathways in HCC. The meta-analysis of a panel of EMT gene expression studies revealed that neuropilin 2
(NRP2) is significantly upregulated in cells that have undergone EMT induced by TGF-β. In this study we assessed the
functional role of NRP2 in epithelial and mesenchymal-like HCC cells and focused on the molecular interplay between
NRP2 and TGF-β/Smad signaling.
Methods: NRP2 expression was analyzed in human HCC cell lines and tissue arrays comprising 133 HCC samples. Cell
migration was examined by wound healing and Transwell assays in the presence and absence of siRNA against NRP2.
NRP2 and TGF-β signaling were analyzed by Western blotting and confocal immunofluorescence microscopy.
Results: We show that NRP2 is particularly expressed in HCC cell lines with a dedifferentiated, mesenchymal-
like phenotype. NRP2 expression is upregulated by the canonical TGF-β/Smad signaling while NRP2 expression
has no impact on TGF-β signaling in HCC cells. Reduced expression of NRP2 by knock-down or inhibition of
TGF-β signaling resulted in diminished cell migration independently of each other, suggesting that NRP2 fails
to collaborate with TGF-β signaling in cell movement. In accordance with these data, elevated levels of NRP2
correlated with a higher tumor grade and less differentiation in a large collection of human HCC specimens.
Conclusions: These data suggest that NRP2 associates with a less differentiated, mesenchymal-like HCC
phenotype and that NRP2 plays an important role in tumor cell migration upon TGF-β-dependent HCC
progression.
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Background
Liver cancer is the sixth most common cancer in the
world and ranks second in the list of most deadly can-
cers [1]. The vast majority of liver cancers are hepatocel-
lular carcinomas (HCC) representing up to 90 % of all
liver malignancies [2, 3]. The main risk factors for HCC
are chronic infections with either hepatitis B virus
(HBV) or hepatitis C virus (HCV), making up approxi-
mately 75–85 % of all cases, as well as excessive alcohol
consumption, which is responsible for about 40 % of
HCC development in Western countries [2, 4–7].
Chronic inflammation and tissue damage by these agents
leads to cirrhosis which is the underlying condition for
the majority of HCC cases [8].
The dissemination of primary tumor cells into the body
drastically worsens the prognosis of cancer patients [9].
Metastasis of HCC cells most frequently occurs intrahepa-
tically rather than extrahepatically to distal sites such as
the lung [10]. For spreading of HCC cells, individual cell
movement by an epithelial to mesenchymal transition
(EMT) has been considered to be essentially involved [11].
Upon EMTand progression in malignancy, highly differen-
tiated epithelial cells such as hepatocytes de-differentiate
into a mesenchymal-like phenotype that exhibits strong
migratory abilities. Various signaling cascades are known
to induce EMT, such as the Wnt/β-catenin, PI3K/AKT/
mTOR, Hedgehog, Ras/Raf/MEK/ERK, Notch and NFκB
pathways, as well as transforming growth factor (TGF)-β
[12–15]. These signals mostly converge on EMT-
transcription factors (EMT-TFs) such as Snail, ZEB1 or
Twist1/2 which transcriptionally repress E-cadherin and
other epithelial junctional proteins as well as activate a
mesenchymal gene expression signature. In HCC, TGF-β
signaling has been shown to activate EMT-TFs and to re-
press their negative feedback loops by the downregulation
of miRNAs that antagonize EMT-TFs [16, 17].
A recently performed meta-analysis compared 24 pub-
lished EMT gene expression data sets and generated a
core list of genes that are most frequently altered during
EMT [18]. One of the genes found upregulated in sev-
eral studies of TGF-β-induced EMT coded for the pro-
tein neuropilin-2 (NRP2). There are two homologs of
the NRP family, NRP1 and NRP2, which are 130 kDa
single-pass transmembrane glycoproteins that act as
non-tyrosine kinase co-receptors [19]. They contain 4
distinct domains including a CUB domain, a FV/FVIII
domain, a MAM domain and a domain that contains the
transmembrane and short cytoplasmic region [20]. Both
homologues can homo- and heteromultimerize [21] and
can bind different members of the semaphorin family, as
well as members of the vascular endothelial growth factor
(VEGF) family [22]. In addition, NRPs are receptors of hep-
atocyte growth factor, platelet-derived growth factor BB,
fibroblast growth factor, epidermal growth factor, placenta
growth factor, and importantly of TGF-β1 [23–25]. NRPs
are therefore critical regulators of angiogenesis, lymphan-
giogenesis and tumor progression. NRP2 expression is cor-
related with lymph node metastasis in breast cancer and
blocking of NRP2 leads to decreased metastasis formation
[26–28]. Clinical data show that high NRP levels, in par-
ticular NRP2, correlate with poor prognosis and survival in
various cancer types [29, 30]. NRP2 was suggested to play a
direct role in EMT and a cross-talk between NRP2 and
TGF-β1 signaling promotes colorectal cancer progression
[31]. In the context of HCC, the role of NRP2 is so far un-
known [32].
In this study, we show that NRP2 expression strongly
correlates with a mesenchymal phenotype in HCC cell
lines and that reduced levels of NRP2 dramatically im-
pair the migratory abilities of HCC cells. We further
provide evidence that NRP2 expression is controlled by
canonical TGF-β signaling, while no direct impact of
NRP2 on TGF-β signaling could be observed. Transla-
tion of these data into the HCC patient situation re-
vealed a correlation of NRP2 levels with a poorly




Tissue arrays contained paraffin-embedded specimens of
tumors and adjacent normal tissue collected from 133
female and male HCC patients. All patients have under-
gone orthotopic liver transplantation for HCC at the De-
partment of Transplantation Surgery, Medical University
of Vienna, between 1982 and 2002, as described [33]. All
specimens were reviewed for histological type and grade
by 2 individual board certified pathologists. 4 μm
thick sections of core biopsies were arrayed in tripli-
cate and stained with anti-NRP2 antibody (R&D Systems,
Minneapolis, USA) or anti-TGF-β1 antibody (Santa Cruz,
Dallas, USA) at a dilution of 1:100. After incubation with
secondary antibodies, visualization was performed
using the vectastain ABC system (Vector Laboratories,
Burlingame, USA). Triplicates of stained tissues were
evaluated by two independent researchers (P.W. and
M.G.) who were blinded regarding patient details. Immu-
nostaining for NRP2 was scored by arbitrary scaling of no
and low-to-high staining. Immunohistochemical analysis of
paraffin-embedded tissues and retrospective analysis of pa-
tient data were approved by the ethics committee of the
Medical University of Vienna.
Cell culture
The human hepatoma cell lines 3p, 3sp, SNU-398, SNU-
423, SNU-449 and SNU-475 were grown in RPMI-1640
medium plus 10 % fetal calf serum (FCS) and antibiotics.
Hep3B, HepG2 and FLC-4 cells were cultivated in
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Eagle’s Minimum Essential Medium (EMEM) plus 10 %
FCS and antibiotics. PLC and HuH-6 cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) plus 10 %
FCS and antibiotics. Human hepatic sinusoidal endothelial
cells (HSECs) received endothelial cell medium (Lonza,
Basel, Switzerland). All cells were kept at 37 °C and 5 %
CO2. TGF-β signaling was stimulated by supplementing
the medium with 2.5 ng/mL TGF-β1 (R&D Systems, Min-
neapolis, USA) for 24 h. For inhibition of TGF-β signaling,
LY2109761 (Santa Cruz, Dallas, USA) antagonizing both
TGF-β receptors I/II was used at a concentration of
10 μM for 24 h. All HCC cell lines were validated by short
tandem repeat analysis.
siRNA knock-down
Cells were seeded on 6-well plates and either transfected
with 80 nM of non-target small interfering (si)RNA or
with 80 nM of siRNA against human NRP2 (Dharmacon,
Town, UK). Cells were processed for further analysis after
48 h of siRNA transfection.
Western blot analysis
Immunoblotting was performed as described [34]. Dilu-
tions of primary antibodies were as follows: NRP2 (R&D
Systems, Minneapolis, USA), 1:1000; β-actin (Sigma, St.
Louis, USA), 1:2500; Smad2/3 (BD Biosciences, NJ,
USA), 1:1000; pSmad2 (Upstate, NY, USA), 1:500; Smad4
(Cell Signaling Technology, Danvers, USA), 1:1000.
Secondary antibodies conjugated to horseradish perox-
idase were used for detection.
Transwell migration and invasion
2.5 × 104 hepatoma cells were resuspended in 100 μL
medium containing 1 % FCS and transferred onto 24-
well cell culture inserts with a pore size of 8 μm (Corn-
ing, Tewksbury, USA). 600 μL medium containing 10 %
FCS was added to lower chambers to generate a gradient
for cell migration. Medium was removed and migrated
cells on membranes were fixed with 4 % paraformaldehyde
after 16 h. Cell nuclei of migrated cells at the bottom side
of the membrane were stained with Hoechst 33342 (Life
Technologies, Green Island, USA) and counted under the
fluorescence microscope (Nikon, Tokyo, Japan). To analyze
cell invasion, 24-well cell culture inserts were coated with
rat-tail collagen (BD Biosciences, NJ, USA) prior to seeding
of hepatoma cells. To examine transendothelial invasion,
2 × 105 HSECs were plated in 100 μL endothelial cell
medium (Lonza, Basel, Switzerland) onto coated 24-well
cell culture inserts and allowed to form a monolayer for
48 h. Subsequently, endothelial cell medium was aspirated
and hepatoma cells were seeded in 100 μL medium con-
taining 1 % FCS onto 24-well inserts. Transmigrated cells
were visualized after 16 h and quantified as described for
cell migration.
Wound healing assay
For studying cell migration in a scratch wound assay,
cells were seeded in 6-well plates and artificial wounds
were inflicted to the cell layer by scratching with sterile
pipette tips. For each condition, three scratches were
inflicted in three independent wells of a 6-well plate.
From each of these scratches eight images were taken
for a total of 24 images per condition and time point.
Images were performed by phase contrast microscopy
(Nikon, Tokyo, Japan) immediately after wounding and
after 24 h. The migrated area of cells into the wound
was quantified with ImageJ software.
Quantitative real-time polymerase chain reaction (qPCR)
RNA isolation was performed using an RNeasy purifica-
tion kit according to the manufacturer’s instructions
(Quiagen, Hilden, Germany). For reverse transcription of
RNA into DNA, the QuantiTect Reverse Transcription kit
was employed (Quiagen, Hilden, Germany). For quantita-
tive RT-PCR (qPCR), aliquots of cDNA were employed for
Fast SYBR green qPCR (Applied Biosystems, Foster City,
USA) and quantified with the 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, USA). RPL41 as
HCC housekeeping gene and the average ΔCT value of the
HCC cell line 3sp were used to calculate the ΔΔCT values
for all cell lines. The ΔΔCT values were used to graph the
fold-change (RQ) via the formula RQ = 2^(−ΔΔCT). Error
bars show SE of ΔΔCT, calculated with the following for-
mula: SE(ΔΔCT) = √((SE(ΔCT Control)^2) ± (SE(ΔCT Tar-
get)^2)). The primer sequences are: NRP2 (forward), 5’-
CTGTGGGTCATCCGTGAGGAC-3’ and NRP2 (reverse)
5’-ATGGGTTCCATGCAGTTCTCCAG-3’; RPL41 (for-
ward), 5’-CAAGTGGAGGAAGAAGCGA-3’ and RPL41
(reverse), 5’-TTACTTGGACCTCTGCCTC-3’.
Confocal immunofluorescence microscopy
Cells were seeded on glass cover slips coated with rat-
tail collagen (BD Biosciences, NJ, USA) and fixed with
4 % formaldehyde. After permeabilization with 0.25 %
Triton-X 100 and blocking with 5 % horse serum, cells
were stained with primary antibody against Smad2/3
(BD Biosciences, NJ, USA) at a concentration of 1:100
and further incubated with secondary antibody (1:200),
phalloidin (1:750) and DAPI (1:1000). Images were ob-
tained by confocal immunofluorescence microscopy
(Zeiss, Oberkochen, Germany).
Statistical analysis
The statistical significance of differences was evaluated
using two-sided Student’s t-test. Data are expressed as
means ± standard deviation (SD) or means ± standard
error of the mean (SEM) for tissue array data.
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Results
NRP2 is upregulated in high-grade HCC and highly
expressed in mesenchymal-like HCC cell lines
We employed a tissue array containing 133 HCC cases
for the analysis of NRP2 expression and found a signifi-
cant correlation of NRP2 levels with higher tumor grading.
While well-differentiated HCC (grade 1) showed NRP2 ex-
pression in 32 % of cases, less-differentiated HCC samples
displayed a nearly twice as much higher frequency of NRP2
presence. In particular, 59 % of HCC with grade 2 and 56 %
of HCC with grade 3 tumors showed NRP2 expression
(Fig. 1a). Generally, NRP2 was found distributed in a patchy
fashion (Fig. 1b) and interestingly, NRP2 was exclusively
expressed in those patient samples that showed TGF-β1 ex-
pression (Additional file 1: Figure S1). Noteworthy, normal
liver did not display NRP2 expression (Fig. 1b) which con-
firmed recent observations that NRP2 is not expressed in
hepatocytes under physiological conditions [35].
To correlate NRP2 expression with differentiation of
hepatoma cells more closely, we analyzed various human
HCC cell lines with differentiated and epithelial traits ver-
sus those exhibiting a de-differentiated and mesenchymal-
like phenotype. Western blot (Fig. 1c) and qPCR analyses
(Fig. 1d) revealed that NRP2 expression strongly corre-
lated with a mesenchymal-like HCC phenotype in 3sp,
SNU-398, SNU-423, SNU-449, SNU-475 and FLC-4 cells.
In contrast, NRP2 was expressed in only one out of five
epithelial HCC cell lines, i.e., HuH-6 cells, and showed un-
detectable levels of NRP2 in the other epithelial 3p,
Hep3B, HepG2 and PLC cells. Together, these data suggest
that NRP2 expression associates with less-differentiated
high-grade tumors and TGF-β1 expression in HCC pa-
tients. In agreement, NRP2 expression was found in de-
differentiated mesenchymal-like HCC cells in vitro which
supports the idea that NRP2 expression correlates with a
de-differentiated phenotype.
NRP2 regulates HCC cell migration and invasion
Next we analyzed the functional impact of NRP2 expres-
sion on cell proliferation and migration. Neither knock-
down nor exogenous overexpression of NRP2 signifi-
cantly affected proliferation kinetics of mesenchymal-
like HCC cells (data not shown). However, Transwell mi-
gration assays employing the mesenchymal-like cell lines
3sp and SNU-449 revealed that reduced expression of
NRP2 results in impaired migratory abilities (Fig. 2a).
Comparable results were obtained in Transwell invasion
and transendothelial migration assays (Fig. 2b, c). In
addition, assessment of cell migration by wound healing
assays of SNU-449 cells confirmed elevated migratory
capabilities dependent on NRP2 (Fig. 2d). Interestingly,
overexpression of NRP2 could not enhance migration or
invasion in any of the employed cell lines (3p, PLC, 3sp,


























































































































Fig. 1 NRP2 expression in primary HCC tissue and HCC cell lines. a NRP2 expression correlated with less differentiated HCC of grade 2 and 3. b
Representative images of no (left) and low-to-high NRP2 expression (right). c, d Western blot (c) and qPCR analysis (d) of epithelial and mesenchymal-
like HCC cells. Expression of actin is shown as loading control. NRP2 expression in 3sp cells was set to a value of 1 to allow comparison of NRP2 levels
in the various cell lines. Error bars depict SD from 3 independent experiments that were performed in triplicates.*, p < 0.05; **, p < 0.01
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that NRP2 is crucially involved in upregulating cell
movement of de-differentiated HCC cells.
TGF-β induces NRP2 in a Smad-dependent fashion
Since NRP2 expression correlated with TGF-β1 expres-
sion (Additional file 1: Figure S1) and TGF-β signaling is
a common trigger of EMT in HCC, we asked whether it
directly influences NRP2 expression in HCC cells. Re-
markably, TGF-β treatment of epithelial 3p, Hep3B and
PLC cells, as well as mesenchymal-like 3sp, SNU-423
and SNU-449 cells resulted in increased NRP2 protein
expression (Fig. 3a). Upregulation of NRP2 was essen-
tially confirmed at transcript levels by qPCR analysis of
epithelial (3p, Hep3B, PLC) and mesenchymal-like HCC
cells (3sp, SNU-423, SNU-449) (Fig. 3b). Interestingly,
blocking of TGF-β signaling by the TGF-β receptor inhibi-
tor LY2109761 resulted in downregulation of NRP2 mRNA
and protein to levels even lower than those of untreated
cells (Fig. 3a–c), suggesting autoregulatory TGF-β loops in
respective HCC cells. Importantly, cells with interference of
canonical TGF-β/Smad signaling by knock-down of Smad4
were insensitive to TGF-β-induced upregulation of NRP2
(Fig. 3c). These data indicate that augmented NRP2 expres-
sion is caused by canonical TGF-β/Smad signaling.
TGF-β-independent activity of NRP2
We next examined whether NRP2 affects canonical
TGF-β signaling in a feedback loop. First, we analyzed
the level of phosphorylated Smad2 protein that displays
TGF-β signaling in SNU-449 cells with and without a
NRP2 knock-down after treatment with TGF-β. No dif-
ference in pSmad2 levels were observed, independently
whether or not NRP2 was expressed (Fig. 4a). To con-
firm these data, we performed confocal immunofluores-
cence analysis of TGF-β-treated NRP2 knock-down cells
and analyzed nuclear Smad2/3 staining (Fig. 4b). In ac-
cordance, no differences in nuclear Smad2/3 localization
between control and NRP2 knock-down cells were de-
tected, suggesting that NRP2 does not influence the ca-
nonical TGF-β/Smad signaling.
Interference with TGF-β signaling also leads to a re-
duced migration of mesenchymal-like HCC cells. Hence,
we further analyzed whether the effect of reduced NRP2
on cell migration is dependent on TGF-β signaling or
not by employing NRP2 knock-down and control cells
after treatment with TGF-β inhibitor LY2109761 (Fig. 4c).
Cells treated with LY2109761 reached approximately
64 % migration efficiency compared to control siNT
cells. NRP2 knock-down cells without inhibitor treat-
ment were even slower migrating, reaching about 33 %
Fig. 2 Loss of NRP2 impairs migration of HCC cells. a Transwell migration of 3sp and SNU-449 cells either untreated or treated with non-target siRNA
(siNT) or siRNA against NRP2 (siNRP2). b, cTranswell invasion (b) and transendothelial invasion (c). d Migration of SNU-449 analyzed by wound healing
assays. Images show migration of cells after 24 h (left panel). Quantification of migrated cells (right panel). The migration of untreated parental SNU-449
cells was set to 100 %. Error bars depict SD from 3 independent experiments that were carried out in triplicates. **, p < 0.01; ***, p < 0.001
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Fig. 4 Effects of NRP2 on TGF-β Signaling and synergistic effects on migration. a Knock-down of NRP2 does not affect phosphorylation of Smad2
(pSmad2) in SNU-449 cells after treatment with 2.5 ng/mL TGF-β1 for 6 h. Actin was used as loading control. b Translocation of Smad2/3 into the
nucleus of SNU-449 cells treated with control siRNA (siNT) or siRNA against NRP2 (siNRP2) after treatment with 2.5 ng/mL TGF-β1 for 1 h. c Transwell assays
of SNU-449 cells assessing the migratory impact of reduced TGF-β signaling by LY2109761 (LY) and diminished NRP2 expression by knock-down (siNRP2),
either alone or in combination. The treatment of cells with non-target siRNA (siNT) was set to 100 %. Error bars depict SD from 3 independent experiments





































































































Fig. 3 NRP2 expression depends on TGF-β/Smad signaling. a NRP2 protein expression after stimulation with 2.5 ng/mL TGF-β1 for 24 h as determined
by Western blotting. Actin is shown as loading control. b qPCR analysis showing NRP2 mRNA levels in epithelial and mesenchymal-like HCC cell lines
treated with either 2.5 ng/mL TGF-β1 or with 10 μM TGF-β inhibitor LY2109761 (LY) for 24 h. c SNU-449 hepatoma cells treated with control siRNA
(siNT) and either administrated with 2.5 ng/mL TGF-β or 10 μM LY2109761 (LY) alone or in combination and analyzed for NRP2 and Smad4 expression
by Western blotting. Smad4 knock-down (siSmad4) of SNU-449 cells treated with 2.5 ng/mL TGF-β1 for 24 h did not show modulation of NRP2 levels.
Error bars depict SD from 3 independent experiments that were performed in triplicates
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of cell motility. Importantly, the cells treated with both
siRNA against NRP2 and LY2109761 migrated even sig-
nificantly slower than those treated with LY2109761
only, reaching about 10 % compared to reference. In
conclusion, these findings indicate that NRP2 has a role
in cell migration that is independent of TGF-β signaling.
Discussion
Of the two neuropilin isoforms, NRP1 is the far more
examined protein. Its role in various types of cancer is
well documented and often linked to angiogenesis via
VEGF. In contrast, few studies were dedicated to NRP2
and its role in tumorigenesis. To our knowledge no at-
tempts were made to elucidate its role in HCC.
In this study, we showed that NRP2 expression corre-
lates with less differentiation in HCC patients as well as
with a de-differentiated, mesenchymal-like phenotype of
HCC cell lines (Fig. 1). Functionally, NRP2 expression se-
verely enhances migration of mesenchymal-like HCC cells
and is induced by the canonical TGF-β/Smad signaling. In
this setting, NRP2 can be considered as a biomarker of
both the activation of TGF-β/Smad signaling and loss of
differentiation by EMT. Thus, NRP2 represents a novel
marker for EMT-transformed cells that can be used apart
from the classical ones such as increased vimentin and N-
cadherin or loss of ZO-1 and E-cadherin expression [36].
Diminished migration of HCC cells was similar either
after reducing NRP2 levels or after blocking TGF-β sig-
naling (Fig. 4c). TGF-β inhibition on its own reduced
NRP2 expression but could not completely block it
(Fig. 3a, b), as the remaining NRP2 levels might allow
cells to better migrate as compared to those cells with
strongly reduced NRP2 levels after RNA interference.
Yet, if HCC cells were blocked for both NRP2 and TGF-
β signaling, a further decrease in HCC cell migration
was observed (Fig. 4c). This additive operation of NRP2
and TGF-β signaling suggests that TGF-β additionally af-
fects cell migration that is independent of NRP2. Moreover,
neither overexpression of exogenous NRP2 nor treatment
with TGF-β1 had any detectable positive effect on migra-
tion (data not shown), suggesting that neither NRP2 ex-
pression nor TGF-β signaling are rate limiting in migration
of mesenchymal-like HCC cell lines. In addition, the conse-
quences of NRP2 expression on migration and invasion as
determined by the passing of cells through unchanged or
collagen-coated Transwell membranes was stronger than
in follow-up experiments in which cells were allowed to
transmigrate through a layer of endothelial cells. This sug-
gests that NRP2 mainly affects the migratory potential of
HCC cells rather than their ability of breaking through
endothelial barriers.
We could show for the first time that NRP2 expression is
tightly controlled by the canonical Smad2/3-Smad4 signal-
ing cascade in HCC cells (Fig. 3c). NRP2 is therefore
considered as an effector of active TGF-β signaling. Interfer-
ence with TGF-β signaling decreases NRP2 expression
below levels of untreated cells (Fig. 3a), indicating autocrine
regulatory TGF-β signaling in mesenchymal-like HCC cells
[37]. In this line, NRP2 expression could be used as marker
of persistent TGF-β activity in HCC patients which is indi-
cative of HCC progression via the tumor promoting arm of
TGF-β [38, 39]. This could explain why NRP2 expression is
associated with higher grading in HCC specimens (Fig. 1a).
Interestingly, no other significant correlations between
NRP2 expression and e.g., tumor staging or vessel invasion
could be found which might be due to limitations in the im-
munohistochemical analysis of tissue arrays.
TGF-β is molecularly linked to NRP2 expression as TGF-
β induces NRP2 levels (Fig. 3a, b). However, we found no
impact of NRP2 on canonical TGF-β signaling (Fig. 4a, b)
despite the fact that NRP2 has been described to act as
TGF-β co-receptor [31]. Interestingly, a role of NRP2 in ca-
nonical TGF-β signaling could also not be confirmed in
lung cancer cells [40], however, this study showed that
NRP2 affected ERK signaling supposedly via non-canonical
TGF-β signaling activity. In HCC cells, we could also not
detect NRP2-driven non-canonical TGF-β signaling (data
not shown). The question how NRP2 exerts its influence
on cell migration remains open. NRP2 could act on other
signaling pathways controlling migration or NRP2 could
directly act as a receptor that conducts signals via its intra-
cellular domain. These aspects are the basis for further in-
vestigations and allow assessing whether NRP2 represents a
valuable target for HCC intervention.
Conclusions
TGF-β shows anti-proliferative and tumor-suppressing
functions in healthy liver tissue but upon HCC develop-
ment, aberrant TGF-β signaling is a major driver of
HCC progression. We found that NRP2 is induced by
canonical TGF-β/Smad signaling in HCC cells and that
NRP2 is a potent regulator of HCC cell migration and
invasion. NRP2 associates with a mesenchymal-like
phenotype in vitro and accordingly, NRP2 correlates
with a higher tumor grade in vivo indicating less differ-
entiation. NRP2 is therefore thought to play an import-
ant role in TGF-β-dependent HCC progression.
Additional file
Additional file 1: Figure S1. Correlation of NRP2 expression and TGF-
β1 expression in vivo. The tissue array comprising 133 HCC patients was
analyzed for TGF-β1 expression and correlated with NRP2 levels. TGF-β1
expression was scored by arbitrary scaling of no, low, medium and high
staining as described [37]. (PDF 34 kb)
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